Effects of selective inhibition of thromboxane synthesis on renal function in humans
Zipser, R.D.
American Journal of Physiology 248(6 Pt 2): F753-F756
1985
ISSN/ISBN: 0002-9513 PMID: 3839111 Document Number: 263993
Thromboxane A2, a potent vasoconstrictor, is a major metabolite of arachidonic acid in the human kidney. To determine the role of thromboxanes in renal hemodynamics, the new thromboxane inhibitor dazmegrel or placebo were administered to 20 healthy volunteers for 14 days in a double-blind protocol. Dazmegrel reduced urinary thromboxane B2 by an average of 68% and serum thromboxane B2 by 79%, without affecting urinary excretion of the prostacyclin metabolite 6-ketoprostaglandin F1.alpha. Neither p-aminohippurate clearance nor inulin clearance were altered by thromboxane inhibition. Thus it is unlikely that thromboxane A2 plays a major role in the regulation of glomerular function in healthy humans.